ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0RIS Circio Holding Asa

15.98
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Circio Holding Asa LSE:0RIS London Ordinary Share NO0013033795 CIRCIO HOLDING ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.98 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Home Health Care Services 10M -432.9M -2.2969 -6.96 3.01B

Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma

03/03/2020 6:17am

PR Newswire (US)


Circio Holding Asa (LSE:0RIS)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Circio Holding Asa Charts.

- The trial is now fully recruited, with a total of 21 patients enrolled

OSLO, Norway, March 3, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that it has completed patient enrollment in the phase I trial with ONCOS-102 in combination with Keytruda (pembrolizumab) in patients with advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma.

In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanoma who have had disease progression on treatment with anti-PD1 CPI. This is a particularly challenging patient population, with few treatment alternatives available. In July 2019, Targovax reported encouraging results from part 1 of the trial  - see link to press release here.

Part 2 of this trial is testing an extended ONCOS-102 dosing regimen with up to twelve injections compared to three injections in part 1. The enrollment of 12 patients into part 2 of the trial has now been completed. The last patients will complete their six months treatment and data on a total of 21 patients are expected in the second half of 2020.

The primary and secondary endpoints of the trial are to assess safety, immune activation and clinical responses of ONCOS-102 and Keytruda combination treatment. The main scientific aim is to test the hypothesis that ONCOS-102 can immune activate anti-PD1 refractory patients to respond to re-challenge with an anti-PD1 CPI.

Magnus Jäderberg, CMO of Targovax, said: "We are very pleased to have completed enrollment of our melanoma trial. ONCOS-102 is currently one of the most clinically advanced oncolytic viruses in this difficult to treat cancer, and therefore a high priority for us. With this trial also being a proof of concept trial, clinical and immune data from this study will not just indicate whether ONCOS-102 in combination with CPIs can help patients with hard to treat melanoma but potentially also other tumor indications.  Supportive data could open the path for a registrational trial."  

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/targovax/r/targovax-announces-completed-enrollment-in-the-oncos-102-trial-in-anti-pd1-refractory-melanoma,c3050994

 

Copyright 2020 PR Newswire

1 Year Circio Holding Asa Chart

1 Year Circio Holding Asa Chart

1 Month Circio Holding Asa Chart

1 Month Circio Holding Asa Chart

Your Recent History

Delayed Upgrade Clock